Johnson & Johnson Innovation

Established in 1973, Johnson & Johnson Innovation facilitates early-stage innovation through strategic partnerships. It connects potential collaborators with resources to advance transformative science and technology across pharmaceuticals, medical devices, and consumer healthcare sectors.

Maciek Drozdz

Principal of Venture Investments

Sanjay Mistry

Vice President, Venture Investments, New Company Creation

Chris Picariello

President

Elizabeth Wu

Director, Early Innovation Partnering

Past deals in Medical Devices

TECLens

Series A in 2025
TECLens designs and manufactures medical vision-correction devices centered on a corneal crosslinking lens for myopia treatment and related conditions. The core product is a non-invasive therapy worn for about 30 minutes in a clinician’s waiting room, with the eye open or closed, delivering real-time ultrasound sensing and precise prescription tuning to reshape the cornea. The lens operates in a high-oxygen environment and uses scleral positioning to maintain stability during treatment. It aims to address presbyopia, slow progression of myopia in children, and corrections for keratoconus and other refractive errors, potentially reducing long-term reliance on traditional corrective lenses. The company is based in St. James, New York.

Cala Health

Series C in 2024
Cala Health is a bioelectronic medicine company that develops wearable neuromodulation therapies for chronic diseases. Its primary product, Cala Trio therapy, is a non-invasive prescription treatment for essential tremor.

G.I. Windows

Series B in 2024
G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, founded in 2012. The company specializes in manufacturing medical devices utilizing advanced surgical anastomotic technology aimed at treating obesity and type 2 diabetes. G.I. Windows is focused on developing innovative solutions that enable less invasive surgical procedures, thereby creating a new category in healthcare. Its technology is designed to enhance the efficiency of diagnostic and interventional procedures, ultimately improving patient outcomes while reducing overall healthcare costs.

SpectraWAVE

Series B in 2024
SpectraWAVE is a medical device company that develops intravascular optical imaging systems to diagnose and treat cardiovascular disease. Its technology integrates imaging and computation to help interventional cardiologists identify vulnerable plaques and guide coronary interventions, improving outcomes for patients with coronary artery disease. Headquartered in Waltham, Massachusetts, the company was founded in 2017.

HistoSonics

Series D in 2024
HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.

Loci Orthopaedics

Series A in 2024
Founded in 2017, Loci Orthopaedics specializes in developing innovative medical technologies for orthopedics. The company is renowned for its InDx implant, the only device that fully mimics natural thumb joint motions and offers a less invasive surgical treatment option.

Nanobiotix

Post in 2023
Nanobiotix SA is a clinical-stage biotechnology company based in Paris, France, focused on advancing cancer treatment through its innovative nanomedicine programs. The company is known for its proprietary NanoXray technology, which enhances the effectiveness of radiotherapy by amplifying its impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its key products, NBTXR3, is a radio-enhancer composed of hafnium oxide designed for treating various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. Founded in 2003, Nanobiotix is dedicated to transforming cancer therapy and improving patient outcomes using its advanced nanotechnology solutions.

Nanobiotix

Post in 2023
Nanobiotix SA is a clinical-stage biotechnology company based in Paris, France, focused on advancing cancer treatment through its innovative nanomedicine programs. The company is known for its proprietary NanoXray technology, which enhances the effectiveness of radiotherapy by amplifying its impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its key products, NBTXR3, is a radio-enhancer composed of hafnium oxide designed for treating various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. Founded in 2003, Nanobiotix is dedicated to transforming cancer therapy and improving patient outcomes using its advanced nanotechnology solutions.

Astraveus

Seed Round in 2023
Astraveus is developing the Lakhesys platform, an end-to-end cell foundry for cell and gene therapy manufacturing. The platform uses deep process optimization and single-use microfluidic bioprocessors to produce autologous therapies with reduced inputs and infrastructure needs, lowering costs and logistical barriers. By enabling automated, patient-specific biomanufacturing, Astraveus aims to improve access to transformative CGTs. The system builds equipment tailored for each patient to use autologous cells, leveraging microfluidic chip technology to convert cells into therapeutic agents. The approach seeks to scale production of cell and gene therapies while minimizing environmental impact and resource use, supporting more sustainable manufacturing at lower cost.

Solenic Medical

Series A in 2023
Founded in 2019, Solenic Medical specializes in the development of a non-invasive medical device that uses alternating magnetic fields to eradicate biofilm on metallic implants. Its technology aims to address complications arising from surgeries like knee and hip replacements, as well as trauma-related implants.

HistoSonics

Convertible Note in 2022
HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.

DocSpera

Series B in 2022
DocSpera is an integrated surgical coordination platform that enhances synchronization across multiple sites and teams, ultimately improving workflow efficiencies and patient care. The company's proprietary platform automates pre-surgical coordination and facilitates real-time, secure synchronization of cases and images among key stakeholders, including surgeons, care teams, and device suppliers, utilizing electronic health record data. Additionally, DocSpera's intelligent surgical planning capabilities allow for continuous patient monitoring from the surgical decision phase through recovery, providing real-time insights and operating room dashboards to support physicians in their decision-making processes. Headquartered in Sunnyvale, California, DocSpera operates under Compliant Innovations Inc.

Verana Health

Series E in 2022
Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQ™, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.

V-Wave

Series C in 2021
V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

Mauna Kea Technologies

Post in 2021
Mauna Kea Technologies is a medical device company that develops, manufactures and markets imaging solutions for real-time cellular-level visualization during minimally invasive procedures to improve cancer and other disease diagnosis and treatment. Its flagship Cellvizio platform combines a probe-based endomicroscopy system that provides in vivo cellular images during procedures, enabling clinicians to assess tissue at the microscopic level in real time. The company serves customers globally, with products cleared or approved in the United States and more than 40 countries, and operates across Europe, the Middle East, Africa, the Americas, and Asia. Mauna Kea aims to eliminate uncertainties in diagnosis and treatment by visualizing tissue in vivo during standard procedures.

FlexDex

Venture Round in 2021
FlexDex Inc. is a medical device company specializing in minimally invasive surgery (MIS) technology. Founded in 2010 and headquartered in Brighton, Michigan, the company has developed a platform that translates a surgeon's hand, wrist, and arm movements from outside the patient into precise movements of an end-effector inside the body. This innovative approach enhances the capabilities of MIS instruments and endoscopes, providing healthcare professionals with improved dexterity and control during surgical procedures. FlexDex serves its market through a network of distributors both in the United States and internationally.

Thirty Madison

Series C in 2021
Thirty Madison is a digital health company specializing in personalized treatments for chronic conditions. It operates platforms like Keeps (hair loss), Cove (migraines), Picnic (allergies), Facet (skin conditions), and Nurx (sexual health). Founded in 2016, it aims to empower individuals with accessible, effective care tailored to their specific needs.

Cue

Private Equity Round in 2021
Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

TechsoMed

Series B in 2021
TechsoMed is an Israeli medical device company specializing in the development of ultrasound-based real-time monitoring systems for thermal ablation procedures. These procedures have wide-ranging applications, including tumor destruction, treatment of heart arrhythmias, and blood pressure management. Despite a market size in the billions, these procedures often suffer from high failure rates due to the lack of real-time monitoring capabilities. TechsoMed's technology addresses this issue by providing physicians with the ability to monitor tissue destruction in real time, thereby enhancing the effectiveness of these minimally invasive and cost-effective treatments for patients, physicians, and insurance companies alike.

Paige

Series C in 2021
Paige is a company focused on computational pathology, developing an AI-powered platform that assists pathologists in diagnosing cancer and guiding treatment decisions. The platform integrates deep learning models, including convolutional and recurrent neural networks and generative methods, to enable rapid diagnostic stratification and cancer detection, with emphasis on breast and prostate cancers. Designed to improve diagnostic confidence and workflow efficiency, Paige's lightweight solution aims to minimize IT burden while ensuring patient safety and data privacy. Paige holds a FDA Breakthrough designation for computational pathology products, highlighting its role in advancing pathology through automated analysis of tissue slides. The company targets clinical researchers and pathology teams with tools that deliver insights to support precise diagnoses and better patient outcomes.

V-Wave

Series C in 2020
V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

G.I. Windows

Series A in 2020
G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, founded in 2012. The company specializes in manufacturing medical devices utilizing advanced surgical anastomotic technology aimed at treating obesity and type 2 diabetes. G.I. Windows is focused on developing innovative solutions that enable less invasive surgical procedures, thereby creating a new category in healthcare. Its technology is designed to enhance the efficiency of diagnostic and interventional procedures, ultimately improving patient outcomes while reducing overall healthcare costs.

Thirty Madison

Series B in 2020
Thirty Madison is a digital health company specializing in personalized treatments for chronic conditions. It operates platforms like Keeps (hair loss), Cove (migraines), Picnic (allergies), Facet (skin conditions), and Nurx (sexual health). Founded in 2016, it aims to empower individuals with accessible, effective care tailored to their specific needs.

Cue

Series C in 2020
Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

HistoSonics

Series C in 2020
HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.

Gatt

Series B in 2020
GATT Technologies BV, established in 2011 and headquartered in Nijmegen, the Netherlands, specializes in developing innovative medical devices. The company focuses on creating synthetic surgical hemostat and sealant products designed to control severe bleeding and organ leakages during surgical procedures. Their product portfolio includes GATT-Patch, a hemostatic sealing patch for general surgery; GATT-Tape, an adhesive tape for preventing intestinal anastomotic leakage; GATT-Spray, an elastic sealant for general surgery; and GATT-Powder, a hemostatic sealing powder. These products are based on a patented synthetic technology, aiming to address challenging surgical bleeding and leakage issues.

OrthoSpin

Series B in 2020
OrthoSpin Limited is a medical technology company based in Misgav, Israel, founded in 2014. It specializes in the development of innovative robotic external fixation systems designed to enhance patient treatment for bone injuries and limb deformities. The company's dynamic external fixators aim to address the challenges associated with traditional systems, which can be cumbersome and painful while requiring significant maintenance. OrthoSpin's proprietary technology incorporates a lightweight motor and a control box that facilitate automatic, continuous adjustments to the fixation frame without patient involvement. This smart system not only helps ensure that prescribed treatment protocols are followed but also allows physicians to monitor patient progress in real-time and make necessary adjustments to treatment plans. The company's focus on improving clinical outcomes and reducing complications positions it as a significant player in the orthopedic field.

Mauna Kea Technologies

Post in 2019
Mauna Kea Technologies is a medical device company that develops, manufactures and markets imaging solutions for real-time cellular-level visualization during minimally invasive procedures to improve cancer and other disease diagnosis and treatment. Its flagship Cellvizio platform combines a probe-based endomicroscopy system that provides in vivo cellular images during procedures, enabling clinicians to assess tissue at the microscopic level in real time. The company serves customers globally, with products cleared or approved in the United States and more than 40 countries, and operates across Europe, the Middle East, Africa, the Americas, and Asia. Mauna Kea aims to eliminate uncertainties in diagnosis and treatment by visualizing tissue in vivo during standard procedures.

TechsoMed

Venture Round in 2019
TechsoMed is an Israeli medical device company specializing in the development of ultrasound-based real-time monitoring systems for thermal ablation procedures. These procedures have wide-ranging applications, including tumor destruction, treatment of heart arrhythmias, and blood pressure management. Despite a market size in the billions, these procedures often suffer from high failure rates due to the lack of real-time monitoring capabilities. TechsoMed's technology addresses this issue by providing physicians with the ability to monitor tissue destruction in real time, thereby enhancing the effectiveness of these minimally invasive and cost-effective treatments for patients, physicians, and insurance companies alike.

Cala Health

Series C in 2019
Cala Health is a bioelectronic medicine company that develops wearable neuromodulation therapies for chronic diseases. Its primary product, Cala Trio therapy, is a non-invasive prescription treatment for essential tremor.

OrthoSpin

Venture Round in 2018
OrthoSpin Limited is a medical technology company based in Misgav, Israel, founded in 2014. It specializes in the development of innovative robotic external fixation systems designed to enhance patient treatment for bone injuries and limb deformities. The company's dynamic external fixators aim to address the challenges associated with traditional systems, which can be cumbersome and painful while requiring significant maintenance. OrthoSpin's proprietary technology incorporates a lightweight motor and a control box that facilitate automatic, continuous adjustments to the fixation frame without patient involvement. This smart system not only helps ensure that prescribed treatment protocols are followed but also allows physicians to monitor patient progress in real-time and make necessary adjustments to treatment plans. The company's focus on improving clinical outcomes and reducing complications positions it as a significant player in the orthopedic field.

Zebra Medical Vision

Series C in 2018
Zebra Medical Vision is an Israel-based company that develops an imaging analytics platform for healthcare. The platform supplies clinicians with imaging research tools, provides advanced learning and computer-vision diagnostic algorithms for developers, and offers risk management and preventative care tools for providers. The company also offers researchers access to tools and datasets to accelerate the development of decision-support and diagnostic technologies. Founded in 2014 and headquartered in Shefayim, Zebra Medical Vision collaborates with partners such as USARAD Holdings and TELUS Ventures and has deployed its AI-enabled imaging analytics across hospitals worldwide.

NeuroVision Imaging

Series C in 2018
NeuroVision Imaging is a neuroscience company that develops diagnostic tests and biomarkers for early detection and monitoring of amyloid pathology related to Alzheimer’s disease. It has developed a retinal imaging technology that is low-cost, non-invasive, and capable of measuring retinal autofluorescence to assess amyloid-beta plaque accumulation in the brain, enabling physicians to diagnose Alzheimer’s disease more efficiently. The company also provides data aggregation, analysis, biostatistics, and machine learning applications to large repositories of images and biomarker data to advance understanding and prediction of neurodegenerative diseases. It serves customers in the United States and internationally and was founded in 2010, with its headquarters in Sacramento, California.

Cala Health

Series A in 2014
Cala Health is a bioelectronic medicine company that develops wearable neuromodulation therapies for chronic diseases. Its primary product, Cala Trio therapy, is a non-invasive prescription treatment for essential tremor.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.